Core Insights - The Dividend Aristocrats are experiencing a strong start to 2026, with the ProShares S&P 500 Dividend Aristocrat ETF (NOBL) increasing by 5.67% in January [1] Group 1: Performance Metrics - The ProShares S&P 500 Dividend Aristocrat ETF (NOBL) has shown a positive performance trend, indicating strong investor interest and confidence in dividend-paying stocks [1]

As you can tell, our core style is to provide actionable and unambiguous ideas from our independent research. If your share this investment style, check out Envision Early Retirement. It provides at least 1x in-depth articles per week on such ideas.We have helped our members not only to beat S&P 500 but also avoid heavy drawdowns despite the extreme volatilities in BOTH the equity AND bond market.Join for a trial and see if our proven method can help you too. ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium also includes the Zacks Style Scores. ...

AbbVie to Present at the TD Cowen 46th Annual Health Care Conference [Accessibility Statement] Skip NavigationNORTH CHICAGO, Ill., Feb. 24, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026. Management will participate in a fireside chat at 10:10 a.m. Central Time.A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at [investors.abbvie.com]. An archived edition of the sess ...

AbbVie on Monday said it would invest $380 million to build two new active pharmaceutical ingredient manufacturing facilities at its Illinois campus, expanding its domestic production capacity for its... ...

Core Insights - AbbVie announced a $380 million investment to build two new active pharmaceutical ingredient (API) manufacturing facilities in North Chicago, Illinois, aimed at enhancing its production capabilities for next-generation neuroscience and obesity medications [1][2] - The construction is set to begin in spring 2026, with both facilities expected to be operational by 2029, and will create approximately 300 new jobs in the region [1][2] - This investment is part of AbbVie's broader $100 billion commitment to U.S. research and development (R&D) and capital investments over the next decade [1] Company Expansion - The new facilities will incorporate advanced manufacturing technologies, including artificial intelligence, to improve the production process [1] - AbbVie has been actively expanding its API manufacturing capabilities in the U.S., with a recent announcement of a new chemical synthesis facility that will bring back production for select neuroscience, immunology, and oncology products from Europe and Asia [2] - The company currently employs around 29,000 people in the U.S., with over 6,000 at its manufacturing sites, and has a significant presence in Illinois, where it employs more than 11,500 people [2] Future Investments - AbbVie is also planning to acquire a device manufacturing facility in Arizona and make significant investments in its Massachusetts manufacturing facility [2] - The company is in discussions with multiple U.S. states regarding potential manufacturing investments and anticipates announcing additional investments in 2026 [2]

Core Insights - Johnson & Johnson (JNJ) and AbbVie (ABBV) are prominent pharmaceutical companies with strong positions in immunology, oncology, and neuroscience, alongside J&J's extensive medical devices business [1] - Both companies are facing patent challenges, necessitating effective pipeline execution and business development for sustained growth [2] Company Overview Johnson & Johnson (JNJ) - JNJ's diversified business model includes pharmaceuticals and medical devices, with over 275 subsidiaries and 28 products generating over $1 billion in annual sales [4] - The Innovative Medicine unit showed a 4.1% organic sales growth in 2025, driven by key drugs like Darzalex and new products [5] - JNJ's MedTech business saw a 4.3% organic sales increase in 2025, supported by acquisitions and improvements in various segments [6] - Significant R&D investments exceeding $32 billion in 2025, with new product approvals expected to drive future growth [7] - JNJ anticipates that 10 new products could achieve peak sales of $5 billion each [8] AbbVie (ABBV) - AbbVie successfully transitioned from the loss of exclusivity (LOE) of Humira by launching new immunology drugs, Skyrizi and Rinvoq, which contributed to a combined sales growth of over 40% in 2025 [9][10] - The neuroscience portfolio also saw a nearly 20% sales increase, driven by products like Botox and Vraylar [12] - AbbVie has invested over $5 billion in acquisitions to enhance its early-stage pipeline, particularly in immunology [13] - The aesthetics segment faced challenges, with global sales declining by 5.9% in 2025 [14] Financial Performance - JNJ's stock rose 48% in the past year, while AbbVie's stock increased by 10.2%, both outperforming the industry average of 12.1% [20] - The Zacks Consensus Estimate for JNJ's 2026 sales and EPS indicates a year-over-year increase of 6.5% and 7.0%, respectively [15] - AbbVie's 2026 sales and EPS estimates imply a year-over-year increase of 9.4% and 8.74%, respectively [17] Valuation and Yield - AbbVie appears more attractive from a valuation perspective, trading at a forward P/E ratio of 15.25 compared to JNJ's 20.79 [20] - AbbVie offers a higher dividend yield of approximately 3.1%, compared to JNJ's 2.1% [23] Future Outlook - AbbVie expects high single-digit revenue growth through 2029, driven by Skyrizi and Rinvoq, with no significant LOE events anticipated [27] - JNJ aims for approximately $100 billion in revenues in 2026, with expectations of sales growth across both segments [28] - Both companies are positioned for continued growth, with JNJ showing a slight edge in stock performance and analyst estimates [29]

IDEAYA Biosciences Announces Appointment of Dr. Theodora (Theo) Ross, M.D., Ph.D., as Chief Development Officer [Accessibility Statement] Skip NavigationSOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced the appointment of Dr. Theodora (Theo) Ross into the newly created role of Chief Development Officer. In this role, Dr. Ross will be responsible for leading early clinical development for IDEAYA's ...

Business Operations - AbbVie operates as a single global business segment focused on innovative medicines and therapies, enabling resource allocation and performance assessment on a global basis[15]. - AbbVie’s commercial efforts are organized by geographic region or therapeutic area, enhancing market reach and operational efficiency[15]. - AbbVie engages in various arrangements, including acquisitions and licensing agreements, to enhance its product development and market presence[58][59]. Product Portfolio - AbbVie's immunology products, including Skyrizi and Rinvoq, address unmet needs in autoimmune diseases, with Skyrizi approved for conditions like plaque psoriasis and Crohn's disease in major markets[16][18]. - Humira, a key product, is approved for multiple autoimmune diseases in North America and the European Union, including rheumatoid arthritis and ulcerative colitis[22]. - AbbVie's oncology portfolio includes Imbruvica and Venclexta, targeting blood cancers, with Imbruvica being one of the first therapies to receive FDA Breakthrough Therapy Designation[28][29]. - The aesthetics portfolio, including Botox Cosmetic and Juvederm Collection, holds market-leading positions in the U.S. and key global markets[33][34]. - AbbVie is expanding its product offerings in eye care with Ozurdex, indicated for diabetic macular edema and other conditions, available in numerous markets[35]. - AbbVie's key products include Mavyret for hepatitis C treatment, which is approved for chronic HCV genotype 1-6 infection in patients aged 12 and older[39]. - Creon is a pancreatic enzyme therapy for exocrine pancreatic insufficiency, marketed only in the United States[40]. - Linzess, marketed as Constella outside the U.S., treats irritable bowel syndrome with constipation and chronic idiopathic constipation[41]. Research and Development - The company emphasizes a global research and development organization to support product discovery and supply chain management[15]. - AbbVie invests significantly in research and development, focusing on compounds for complex, life-threatening diseases, with integrated project teams enhancing discovery and development[62]. - The research and development process typically takes 8 to 12 years, with no guarantee of regulatory approval for new drugs[64]. - Clinical trials are conducted in phases, with Phase 3 involving a significantly larger patient population to demonstrate efficacy and safety[65]. - AbbVie supplements its R&D efforts through acquisitions, partnering with biotechnology companies and academic institutions to enhance its portfolio[62]. Regulatory Environment - Regulatory approval processes vary by country, with the U.S. FDA requiring successful preclinical tests and clinical trials before marketing approval[67]. - Compliance with regulatory requirements incurs significant costs and can delay product releases, affecting AbbVie's market strategy[77]. - The Inflation Reduction Act of 2022 mandates government-set prices for select high-expenditure Medicare drugs, potentially impacting AbbVie's revenues[84]. - In the European Union, governments regulate pharmaceutical product prices, affecting reimbursement and market access for new products[85]. - Japan's National Health Insurance system sets drug prices and mandates price cuts every other year, impacting AbbVie's pricing strategy[87]. - Emerging markets are increasingly implementing price controls and promoting generics, which may affect AbbVie's competitive positioning[88]. Financial Information - AbbVie's strategic goals include long-term planning and forecasting based on consolidated financial information regularly reviewed by the Chief Operating Decision Maker[15]. - In 2025, three wholesale distributors accounted for substantially all of AbbVie's pharmaceutical product sales in the U.S., with no individual wholesaler exceeding 43% of gross revenues[44]. - AbbVie has a substantial patent portfolio, with key patents for risankizumab and upadacitinib expected to expire in 2033, and no generic entry for Rinvoq tablets expected prior to April 2037[56]. - AbbVie maintains robust supplier relationships and inventory management to mitigate supply disruptions in its manufacturing processes[60][61]. - AbbVie's capital expenditures for pollution control in 2025 were approximately $17 million, with estimated expenditures of $21 million in 2026[96]. - As of December 31, 2025, AbbVie employed approximately 57,000 employees in over 70 countries[98]. - AbbVie has approximately $19.6 billion in total foreign currency forward exchange contracts outstanding as of December 31, 2025[322]. - A 10% appreciation in the underlying currencies being hedged would decrease the fair value of foreign exchange forward contracts by $2.0 billion at December 31, 2025[322]. - An increase in interest rates of 100 basis points would adversely impact the fair value of AbbVie's interest rate swap contracts by approximately $81 million[324]. - The company estimates that an increase of 100 basis points in long-term interest rates would decrease the fair value of long-term debt by $4.5 billion at December 31, 2025[324]. Employee and Environmental Initiatives - AbbVie has invested significantly in equipping employees with foundational artificial intelligence (AI) skills to adapt to evolving work environments[102]. - AbbVie conducts annual pay equity analyses to ensure equal employment opportunity and non-discrimination[105]. - The company believes that its environmental compliance efforts will not have a material adverse effect on its financial position or results of operations[97].

Core Insights - AbbVie reported strong fourth-quarter and full-year 2025 results, surpassing expectations, primarily driven by its newer immunology drugs, Rinvoq and Skyrizi, which offset the decline of the legacy drug Humira [1] Financial Performance - Skyrizi and Rinvoq generated combined revenues of approximately $26 billion, reflecting over 40% year-over-year growth. Skyrizi sales increased by 50% year-over-year to $17.56 billion, while Rinvoq sales rose by 39% to $8.30 billion [2] - AbbVie anticipates overall sales to grow at a high single-digit revenue CAGR through 2029, with combined sales of Skyrizi and Rinvoq expected to exceed $31 billion in 2026, surpassing the long-term guidance of $31 billion for 2027 [4] Market Dynamics - The immunology market is experiencing strong growth, with significant market share gains for Skyrizi in psoriasis and Rinvoq in rheumatoid arthritis. New indications for both drugs, including recent approvals and potential future approvals, are expected to drive further growth [3][5] - AbbVie expects Rinvoq to secure approvals for vitiligo and alopecia areata in 2026, with additional phase III data anticipated for hidradenitis suppurativa and systemic lupus erythematosus [5] Competitive Landscape - AbbVie faces competition from Johnson & Johnson, which markets Stelara and Tremfya, and Eli Lilly, which recently received FDA approval for Omvoh in ulcerative colitis [7][8] Valuation and Estimates - AbbVie shares are currently trading at a P/E ratio of 15.14, below the industry average of 18.74, but above its five-year mean of 13.68 [12] - Estimate revisions for 2026 EPS have trended higher, while those for 2027 have decreased over the past 30 days [14]